Rhumbline Advisers Acquires 754 Shares of Arvinas, Inc. (NASDAQ:ARVN)

Rhumbline Advisers boosted its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN) by 0.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 87,877 shares of the company’s stock after buying an additional 754 shares during the quarter. Rhumbline Advisers owned approximately 0.13% of Arvinas worth $1,685,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in Arvinas by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock valued at $61,000 after acquiring an additional 440 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Arvinas by 0.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company’s stock worth $2,694,000 after purchasing an additional 777 shares during the last quarter. KBC Group NV boosted its position in Arvinas by 77.0% during the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after purchasing an additional 1,255 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Arvinas by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company’s stock valued at $279,000 after purchasing an additional 1,367 shares during the last quarter. Finally, Quantbot Technologies LP raised its holdings in Arvinas by 147.3% in the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after purchasing an additional 2,601 shares in the last quarter. Institutional investors own 95.19% of the company’s stock.

Arvinas Stock Up 1.8 %

Arvinas stock opened at $16.52 on Wednesday. The stock has a 50-day moving average price of $18.32 and a 200 day moving average price of $22.59. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of -5.96 and a beta of 1.95. Arvinas, Inc. has a 52 week low of $15.53 and a 52 week high of $49.76.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period last year, the company earned ($2.53) EPS. Research analysts anticipate that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO John G. Houston sold 31,338 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the sale, the chief executive officer now directly owns 1,157,480 shares of the company’s stock, valued at approximately $19,353,065.60. This represents a 2.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Ian Taylor sold 9,020 shares of Arvinas stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the completion of the transaction, the insider now directly owns 159,121 shares of the company’s stock, valued at $2,658,911.91. The trade was a 5.36 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 41,572 shares of company stock valued at $695,030. Company insiders own 5.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ARVN. Oppenheimer lifted their price objective on shares of Arvinas from $40.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Guggenheim reaffirmed a “buy” rating and issued a $57.00 price target on shares of Arvinas in a report on Wednesday, February 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arvinas in a research report on Friday, February 7th. Stifel Nicolaus lowered their price objective on Arvinas from $63.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, February 12th. Finally, BTIG Research began coverage on Arvinas in a research note on Tuesday, December 10th. They set a “buy” rating and a $69.00 target price on the stock. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $60.00.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.